Research graph
References from Systemic Complement Activation Profiles in Nonexudative Age-Related Macular Degeneration. Local targets link to admitted publications; unresolved targets remain external evidence.
Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis
10.1016/s2214-109x(13)70145-1 · 2014 · External reference
Seeing through VEGF: innate and adaptive immunity in pathological angiogenesis in the eye
10.1016/j.molmed.2014.10.005 · 2015 · External reference
A glimpse at the aging eye
10.1038/npjamd.2016.3 · 2016 · External reference
Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report no. 3
10.1001/jamaophthalmol.2013.7376 · 2014 · External reference
Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial
10.1001/jama.2013.4997 · 2013 · External reference
CFH and ARMS2 genetic risk determines progression to neovascular age-related macular degeneration after antioxidant and zinc supplementation
10.1073/pnas.1718059115 · 2018 · External reference
A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8
10.1001/archopht.119.10.1417 · 2001 · External reference
Long-term effects of vitamins C and E, β-carotene, and zinc on age-related macular degeneration: AREDS report no. 35
10.1016/j.ophtha.2013.01.021 · 2013 · External reference
Complement factor H polymorphism in age-related macular degeneration
10.1126/science.1109557 · 2005 · External reference
Complement factor H variant increases the risk of age-related macular degeneration
10.1126/science.1110359 · 2005 · External reference
Complement factor H polymorphism and age-related macular degeneration
10.1126/science.1110189 · 2005 · External reference
Strong association of the Y402H variant in complement factor H at 1q32 with susceptibility to age-related macular degeneration
10.1086/431426 · 2005 · External reference
Advances in age-related macular degeneration understanding and therapy
2017 · External reference
Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration
10.1016/j.ophtha.2013.09.044 · 2014 · External reference
Targeting factor D of the alternative complement pathway reduces geographic atrophy progression secondary to age-related macular degeneration
10.1126/scitranslmed.aaf1443 · 2017 · External reference
Efficacy and safety of lampalizumab for geographic atrophy due to age-related macular degeneration: Chroma and Spectri phase 3 randomized clinical trials
10.1001/jamaophthalmol.2018.1544 · 2018 · External reference
Complement C3 inhibitor pegcetacoplan for geographic atrophy secondary to age-related macular degeneration
10.1016/j.ophtha.2019.07.011 · 2020 · External reference
C5 inhibitor avacincaptad pegol for geographic atrophy due to age-related macular degeneration
10.1016/j.ophtha.2020.08.027 · 2021 · External reference
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
2020 · External reference
Estimation of systemic complement C3 activity in age-related macular degeneration
10.1001/archopht.125.4.515 · 2007 · External reference
Complement factors and reticular pseudodrusen in intermediate age-related macular degeneration staged by multimodal imaging
10.1136/bmjophth-2019-000361 · 2020 · External reference
Systemic activation of the complement system in patients with advanced age-related macular degeneration
10.1177/1120672119857896 · 2020 · External reference
Elevated plasma levels of C3a complement compound in the exudative form of age-related macular degeneration
10.1159/000219686 · 2009 · External reference
Plasma biomarkers of the amyloid pathway are associated with geographic atrophy secondary to age-related macular degeneration
10.1371/journal.pone.0236283 · 2020 · External reference
A monoclonal antibody targeting amyloid β (Aβ) restores complement factor I bioactivity: potential implications in age-related macular degeneration and Alzheimer’s disease
10.1371/journal.pone.0195751 · 2018 · External reference
Plasma complement components and activation fragments: associations with age-related macular degeneration genotypes and phenotypes
10.1167/iovs.09-3928 · 2009 · External reference
Complement activation levels are related to disease stage in AMD
10.1167/iovs.61.3.18 · 2020 · External reference
Association of imaging biomarkers and local activation of complement in aqueous humor of patients with early forms of age-related macular degeneration
10.1007/s00417-020-04910-6 · 2021 · External reference
Early local activation of complement in aqueous humour of patients with age-related macular degeneration
10.1038/s41433-019-0501-4 · 2019 · External reference
A novel role of complement in retinal degeneration
10.1167/iovs.12-10069 · 2012 · External reference
Complement component C3 plays a critical role in protecting the aging retina in a murine model of age-related macular degeneration
10.1016/j.ajpath.2013.04.008 · 2013 · External reference
The complement system is critical in maintaining retinal integrity during aging
10.3389/fnagi.2018.00015 · 2018 · External reference
C3- and CR3-dependent microglial clearance protects photoreceptors in retinitis pigmentosa
10.1084/jem.20190009 · 2019 · External reference
Reliability of the mouse model of choroidal neovascularization induced by laser photocoagulation
10.1167/iovs.14-15067 · 2014 · External reference
